DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.

@article{Henricks2017DPYDGD,
  title={DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.},
  author={Linda M Henricks and Frans L Opdam and Jos H. Beijnen and Annemieke Cats and Jan H. M. Schellens},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2017},
  volume={28 12},
  pages={2915-2922}
}
The fluoropyrimidine anticancer drugs, especially 5-fluorouracil (5-FU) and capecitabine, are frequently prescribed for several types of cancer, including breast, colorectal, head and neck and gastric cancer. In the current drug labels of 5-FU and capecitabine in the European Union and the United States, no adaptive dosing strategies are incorporated for polymorphic metabolism of 5-FU. Although treatment with fluoropyrimidines is generally well tolerated, a major clinical limitation is that a… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 81 times. VIEW TWEETS